SG Americas Securities LLC Makes New Investment in Bausch Health Companies Inc. (NYSE:BHC)

SG Americas Securities LLC acquired a new stake in Bausch Health Companies Inc. (NYSE:BHC) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 69,179 shares of the company’s stock, valued at approximately $555,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lazard Asset Management LLC purchased a new position in shares of Bausch Health Companies during the second quarter worth about $49,000. Graham Capital Management L.P. acquired a new position in Bausch Health Companies during the second quarter worth about $84,000. FMR LLC grew its holdings in Bausch Health Companies by 58.3% during the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock valued at $84,000 after buying an additional 3,703 shares during the last quarter. Ausdal Financial Partners Inc. purchased a new stake in Bausch Health Companies during the 3rd quarter worth about $86,000. Finally, Jump Financial LLC purchased a new stake in shares of Bausch Health Companies during the third quarter worth about $92,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Price Performance

BHC stock opened at $10.04 on Friday. Bausch Health Companies Inc. has a 52-week low of $5.57 and a 52-week high of $11.46. The firm has a market capitalization of $3.67 billion, a P/E ratio of -6.20 and a beta of 0.85. The company’s 50 day simple moving average is $9.08 and its 200-day simple moving average is $8.09.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The company had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $1.02 EPS. The company’s revenue was up 9.8% compared to the same quarter last year. Sell-side analysts predict that Bausch Health Companies Inc. will post 3.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BHC. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Royal Bank of Canada boosted their price objective on shares of Bausch Health Companies from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Friday, February 23rd. Finally, Jefferies Financial Group decreased their price target on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, February 20th.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.